Scholars Central

Conference abstractPublished 27 Jul 2015

Neural progenitor cells for treating retinal degeneration

Authors: Shaomei Wang, Bin Lu, Yuchun Tsai, Sergey Girman, Benjamin Bakondi, Melissa Jones, Dhruv Sarren, Clive N Svendsen

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Retinal degenerative diseases, such as age-related macular degeneration (AMD) are the major causes of irreversible blindness in industrialized countries. AMD pathogenesis involves a cascade of detrimental events beginning with RPE and Bruchâ??s membrane changes that culminate in the death of light sensing photoreceptor cells and adjacent RPE ultimately leading to central vision loss. Currently no effective treatment options exist to slow disease progression for dry AMD. The use of stem/progenitor cells have shown tremendous promise for treating retinal degenerative diseases and three concurrent clinical trials for dry AMD are underway in the US (ClinicalTrials.gov) and one trial for wet AMD in Japan. The clinical strategies for these trials are to use stem/progenitor cells to either replace the compromised host RPE, or to implant cells that limit ongoing RPE degeneration by undefined mechanisms. Our extensive studies demonstrated that human neural progenitor cells (NPCs) derived from induced pluripotent stem cells (iNPCs) or fetal cortex (a) have excellent survival with no evident induction of host immune rejection even in this xenogeic condition; (b) offer dramatic and prolonged preservation of both photoreceptors and visual function; (c) migrate long distance from the injection site next to photoreceptor layer; and (d) offer sustained release of multiple growth factors as well as provide other functions such as cell-cell contact and/or extracellular matrix (ECM) that enhance the survival of grafted cells and host retina. iNPCs avoid allograft immunogenicity and ethical concern, and allows for limitless production, represent a promising cell source for future personalized therapies.

Subjects

Engineering

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Tissue Science and Engineering.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Tissue Science and Engineering
  • SubjectEngineering
  • BylineArticles whose byline prints “Shaomei Wang”
  • BylineArticles whose byline prints “Bin Lu”
  • BylineArticles whose byline prints “Yuchun Tsai”
  • BylineArticles whose byline prints “Sergey Girman”
  • BylineArticles whose byline prints “Benjamin Bakondi”
  • BylineArticles whose byline prints “Melissa Jones”
  • BylineArticles whose byline prints “Dhruv Sarren”
  • BylineArticles whose byline prints “Clive N Svendsen”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels